Mei Pharma Stock Analysis

MEI Stock Analysis Notes

About 41.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.71. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. MEI Pharma recorded a loss per share of 5.73. The entity last dividend was issued on the 16th of November 2023. The firm had 1:20 split on the 17th of April 2023. MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California. Mei Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 102 people. To find out more about MEI Pharma contact Justin CPA at 858 369 7100 or learn more at https://meipharma.com.

MEI Pharma Investment Alerts

MEI Pharma Upcoming and Recent Events

MEI Largest EPS Surprises

View All Earnings Estimates

MEI Pharma Environmental, Social, and Governance (ESG) Scores

MEI Pharma Thematic Classifications

MEI Stock Institutional Investors

Note, although MEI Pharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

MEI Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 15.32 M.

MEI Profitablity

Management Efficiency

MEI Pharma has return on total asset (ROA) of (0.3068) % which means that it has lost $0.3068 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9368) %, meaning that it created substantial loss on money invested by shareholders. MEI Pharma's management efficiency ratios could be used to measure how well MEI Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/14/2025, Return On Tangible Assets is likely to grow to 0.41. Also, Return On Capital Employed is likely to grow to 0.42. At this time, MEI Pharma's Liabilities And Stockholders Equity is relatively stable compared to the past year. As of 03/14/2025, Non Current Liabilities Other is likely to grow to about 26.8 M, while Total Current Liabilities is likely to drop slightly above 8.3 M.

Technical Drivers

As of the 14th of March 2025, MEI Pharma secures the mean deviation of 1.65, and Risk Adjusted Performance of (0.08). In connection with fundamental indicators, the technical analysis model lets you check helpful technical drivers of MEI Pharma, as well as the relationship between them.

MEI Pharma Price Movement Analysis

MEI Pharma Insider Trading Activities

MEI Pharma Outstanding Bonds

MEI Pharma Predictive Daily Indicators

MEI Pharma Corporate Filings

MEI Pharma Forecast Models

MEI Pharma's time-series forecasting models are one of many MEI Pharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary MEI Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how MEI Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling MEI shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as MEI Pharma. By using and applying MEI Stock analysis, traders can create a robust methodology for identifying MEI entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. MEI analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. MEI analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

MEI Pharma stock analysis indicators help investors evaluate how MEI Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading MEI Pharma shares will generate the highest return on investment. By understating and applying MEI Pharma stock analysis, traders can identify MEI Pharma position entry and exit signals to maximize returns.

When running MEI Pharma's price analysis, check to measure MEI Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MEI Pharma is operating at the current time. Most of MEI Pharma's value examination focuses on studying past and present price action to predict the probability of MEI Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MEI Pharma's price. Additionally, you may evaluate how the addition of MEI Pharma to your portfolios can decrease your overall portfolio volatility.